$ZYME
Zymeworks Inc.

2024 Q3 Form 10-Q Financial Statement

#000193765324000041 Filed on August 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $16.00M $19.24M
YoY Change -3.07% 174.82%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.85M $15.68M
YoY Change -18.52% -27.77%
% of Gross Profit
Research & Development $36.35M $29.16M
YoY Change 10.92% -26.0%
% of Gross Profit
Depreciation & Amortization $2.015M $1.907M
YoY Change -32.83% -27.19%
% of Gross Profit
Operating Expenses $36.35M $29.16M
YoY Change 10.92% -26.0%
Operating Profit -$34.21M -$42.89M
YoY Change 2.91% -20.75%
Interest Expense $4.785M $5.154M
YoY Change -4.8% 6.82%
% of Operating Profit
Other Income/Expense, Net -$204.0K $114.0K
YoY Change -132.18% -154.55%
Pretax Income -$29.62M -$37.62M
YoY Change 7.42% -24.0%
Income Tax $226.0K $68.00K
% Of Pretax Income
Net Earnings -$29.85M -$37.69M
YoY Change 4.05% -26.33%
Net Earnings / Revenue -186.56% -195.84%
Basic Earnings Per Share -$0.39 -$0.49
Diluted Earnings Per Share -$0.39 -$0.49
COMMON SHARES
Basic Shares Outstanding 71.05M shares 70.70M shares
Diluted Shares Outstanding 76.16M shares 76.40M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $297.2M $330.1M
YoY Change 0.61% -2.92%
Cash & Equivalents $122.4M $70.96M
Short-Term Investments $174.8M $259.2M
Other Short-Term Assets $22.87M $21.27M
YoY Change 90.54% -32.33%
Inventory
Prepaid Expenses
Receivables $23.70M $32.08M
Other Receivables $0.00 $0.00
Total Short-Term Assets $343.8M $383.5M
YoY Change -8.24% -8.76%
LONG-TERM ASSETS
Property, Plant & Equipment $18.33M $18.47M
YoY Change -12.3% -17.45%
Goodwill $12.02M $12.02M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $77.67M $65.79M
YoY Change -18.84% -28.67%
Other Assets $11.43M $11.13M
YoY Change 17.88% 20.01%
Total Long-Term Assets $143.4M $132.1M
YoY Change -21.1% -27.28%
TOTAL ASSETS
Total Short-Term Assets $343.8M $383.5M
Total Long-Term Assets $143.4M $132.1M
Total Assets $487.2M $515.6M
YoY Change -12.44% -14.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.423M $1.733M
YoY Change -68.88% -88.07%
Accrued Expenses $50.39M $44.27M
YoY Change -14.0% -23.6%
Deferred Revenue $27.19M $5.520M
YoY Change 29134.41% -68.93%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $83.91M $54.71M
YoY Change 15.19% -41.51%
LONG-TERM LIABILITIES
Long-Term Debt $33.00K $33.00K
YoY Change -67.0% -72.95%
Other Long-Term Liabilities $929.0K $1.229M
YoY Change -50.0% -65.83%
Total Long-Term Liabilities $929.0K $1.229M
YoY Change -50.0% -65.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $83.91M $54.71M
Total Long-Term Liabilities $929.0K $1.229M
Total Liabilities $120.2M $109.5M
YoY Change -8.97% -28.51%
SHAREHOLDERS EQUITY
Retained Earnings -$797.8M -$746.8M
YoY Change 20.35% 17.74%
Common Stock $1.163B $1.153B
YoY Change 7.03% 6.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $367.0M $406.2M
YoY Change
Total Liabilities & Shareholders Equity $487.2M $515.6M
YoY Change -12.44% -14.35%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$29.85M -$37.69M
YoY Change 4.05% -26.33%
Depreciation, Depletion And Amortization $2.015M $1.907M
YoY Change -32.83% -27.19%
Cash From Operating Activities -$5.877M -$24.99M
YoY Change -86.24% 290.53%
INVESTING ACTIVITIES
Capital Expenditures $1.002M $1.096M
YoY Change -8.91% 36.66%
Acquisitions
YoY Change
Other Investing Activities $73.26M -$18.88M
YoY Change -1341.68% -68.47%
Cash From Investing Activities $72.26M -$19.97M
YoY Change -1132.24% -67.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -14.98M 1.048M
YoY Change -888.37% -96.2%
NET CHANGE
Cash From Operating Activities -5.877M -24.99M
Cash From Investing Activities 72.26M -19.97M
Cash From Financing Activities -14.98M 1.048M
Net Change In Cash 51.40M -43.91M
YoY Change -207.53% 11.25%
FREE CASH FLOW
Cash From Operating Activities -$5.877M -$24.99M
Capital Expenditures $1.002M $1.096M
Free Cash Flow -$6.879M -$26.09M
YoY Change -84.29% 262.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Income Loss
NetIncomeLoss
-69339000 usd
us-gaap Depreciation
Depreciation
2156000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1514000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8107000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1171000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
157557000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-51152000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-69339000 usd
CY2024Q2 zyme Fair Value Option Adjustment For Change In Fair Value Of Liability Classified Stock Options
FairValueOptionAdjustmentForChangeInFairValueOfLiabilityClassifiedStockOptions
-51000 usd
CY2023Q2 zyme Fair Value Option Adjustment For Change In Fair Value Of Liability Classified Stock Options
FairValueOptionAdjustmentForChangeInFairValueOfLiabilityClassifiedStockOptions
-49000 usd
zyme Fair Value Option Adjustment For Change In Fair Value Of Liability Classified Stock Options
FairValueOptionAdjustmentForChangeInFairValueOfLiabilityClassifiedStockOptions
-201000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-37737000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-51201000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-69540000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76392593 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67281028 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76303713 shares
CY2024Q2 zyme Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Liability Classified
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsLiabilityClassified
3624 shares
CY2023Q2 zyme Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Liability Classified
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsLiabilityClassified
3483 shares
zyme Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Liability Classified
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsLiabilityClassified
18228 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76396217 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67284511 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2024Q2 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.649
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0408
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y14D
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-439000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
346000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
53000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
230000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
72000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
114000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-209000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
418000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2839000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17192000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
20031000 usd
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
24000 usd
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
33000 usd
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
57000 usd
CY2024Q2 zyme Lease Liability
LeaseLiability
20088000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
778000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
972000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27287000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-198896000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
334000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
142100000 usd
CY2024Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
341000 usd
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
17628000 usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1 shares
CY2023Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
CY2024Q2 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
CY2023Q4 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
492956000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1648000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
371000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2196000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24353000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
720000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q2 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 usd
CY2023Q2 zyme Stock Issued During Period Value New Issues At The Market Program Net Of Issuance Costs
StockIssuedDuringPeriodValueNewIssuesAtTheMarketProgramNetOfIssuanceCosts
26233000 usd
us-gaap Net Income Loss
NetIncomeLoss
-75505000 usd
us-gaap Depreciation
Depreciation
3525000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1357000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2692000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2535000 usd
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
17287000 usd
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
0 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
232000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-115000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1878000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
499000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
724000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-139000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12609000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
15417000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3716000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6003000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
458000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-17575000 usd
zyme Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-6799000 usd
zyme Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1681000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1821000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
15411000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
124000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
318000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62659000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89590000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26233000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2876000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2907000 usd
zyme Proceeds From Issuance Of Shares Under Employee Share Purchase Plan
ProceedsFromIssuanceOfSharesUnderEmployeeSharePurchasePlan
386000 usd
zyme Proceeds From Issuance Of Shares Under Employee Share Purchase Plan
ProceedsFromIssuanceOfSharesUnderEmployeeSharePurchasePlan
236000 usd
zyme Payments Of Deferred Financing Fees
PaymentsOfDeferredFinancingFees
82000 usd
zyme Payments Of Deferred Financing Fees
PaymentsOfDeferredFinancingFees
27000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
9000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
9000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3171000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29340000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
177236000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
366255000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
151699000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
168547000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1188000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-86594000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-258812000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
400912000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70963000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
394000 usd
us-gaap Nature Of Operations
NatureOfOperations
Nature of Operations<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zymeworks Inc. together with its subsidiaries (collectively the “Company” or “Zymeworks”) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks BC Inc. (“Zymeworks BC”), (previously known as “Zymeworks Inc.”) was incorporated on September 8, 2003 under the laws of the Canada Business Corporations Act. On October 22, 2003, the Company was registered as an extra-provincial company under the Company Act (British Columbia). On May 2, 2017, the Company continued under the Business Corporations Act (British Columbia).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has devoted substantially all of its resources to research and development activities, including developing its therapeutic platforms and identifying and developing potential product candidates by undertaking preclinical studies and clinical trials. The Company supports these activities through general and administrative support, as well as by raising capital, conducting business planning and protecting its intellectual property. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2022, the Company completed an internal reorganization transaction resulting in a Delaware incorporated entity becoming the listed company (the “Redomicile Transactions”). Prior to the Redomicile Transactions, the shares of Zymeworks BC Inc. (formerly known as Zymeworks Inc.) were publicly listed. Unless the context otherwise requires or otherwise expressly states, all references in the accompanying consolidated financial statements to “Zymeworks,” the “Company,” “we,” “us” and “our” (i) for periods until completion of the Redomicile Transactions, refer to Zymeworks BC Inc. and its subsidiaries and (ii) for periods after completion of the Redomicile Transactions, refer to Zymeworks Inc. (formerly known as Zymeworks Delaware Inc.) and its subsidiaries. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To effect the Redomicile Transactions, the Company conducted a share exchange, pursuant to which holders of the Company’s common shares exchanged their common shares in the Company for shares of common stock of Zymeworks Inc. (formerly known as Zymeworks Delaware Inc.) or, at their election with respect to all or a portion of their common shares in the Company and subject to applicable eligibility criteria and an overall cap, exchangeable shares (the “Exchangeable Shares”) in the capital of a newly formed indirect subsidiary of Zymeworks Inc. A special meeting of Company security holders was held on October 7, 2022 to approve the Redomicile Transactions. The Redomicile Transactions were governed by a transaction agreement dated July 14, 2022, as restated and amended on August 18, 2022 (the “Restated and Amended Transaction Agreement”), by and among the Company and its direct or indirect subsidiaries Zymeworks Inc., Zymeworks CallCo ULC (“CallCo”) and Zymeworks ExchangeCo Ltd., (“ExchangeCo”) including a plan of arrangement included as Exhibit A to the Restated and Amended Transaction Agreement (the “Plan of Arrangement”).</span></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of interim condensed consolidated financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, most notably those related to revenue recognition including estimated timing of completion of performance obligations required to meet revenue recognition criteria, accrual of expenses including clinical and preclinical study expense accruals, stock-based compensation, valuation allowance for deferred taxes, measurement of contingent consideration liabilities, and other contingencies. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</span></div>
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37686000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-75505000 usd
zyme Fair Value Option Adjustment For Change In Fair Value Of Liability Classified Stock Options
FairValueOptionAdjustmentForChangeInFairValueOfLiabilityClassifiedStockOptions
-109000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-75614000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67011664 shares
zyme Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Liability Classified
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsLiabilityClassified
3130 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76321941 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67014794 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.13
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.13
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
326222000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-1245000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
324977000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
298644000 usd
CY2023 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
56000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
298700000 usd
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
395940000 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
456257000 usd
CY2024Q2 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
17287000 usd
CY2024Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
341000 usd
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
17628000 usd
CY2023 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 unit
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2024Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1733000 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6212000 usd
CY2024Q2 zyme Accrued Research Expenses Current
AccruedResearchExpensesCurrent
36096000 usd
CY2023Q4 zyme Accrued Research Expenses Current
AccruedResearchExpensesCurrent
26661000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3937000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6153000 usd
CY2024Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
304000 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
960000 usd
CY2024Q2 zyme Accrued Legal And Professional Fees Current
AccruedLegalAndProfessionalFeesCurrent
1397000 usd
CY2023Q4 zyme Accrued Legal And Professional Fees Current
AccruedLegalAndProfessionalFeesCurrent
3707000 usd
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 usd
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1570000 usd
CY2024Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
953000 usd
CY2023Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
729000 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
44420000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
45992000 usd
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0 usd
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
308000 usd
CY2024Q2 zyme Liabilities From In Licensing Agreements
LiabilitiesFromInLicensingAgreements
747000 usd
CY2023Q4 zyme Liabilities From In Licensing Agreements
LiabilitiesFromInLicensingAgreements
747000 usd
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
33000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
92000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
449000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
554000 usd
CY2024Q2 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
1229000 usd
CY2023Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
1701000 usd
CY2024Q2 zyme All Classes Of Stock Shares Authorized
AllClassesOfStockSharesAuthorized
1000000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 zyme Exchangeable Shares Outstanding
ExchangeableSharesOutstanding
570637 shares
CY2023Q4 zyme Exchangeable Shares Outstanding
ExchangeableSharesOutstanding
651219 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4903136 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4594639 shares
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2876000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.677
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0380
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
zyme Share Based Compensation By Share Based Payment Award Unamortized Compensation Expense
ShareBasedCompensationByShareBasedPaymentAwardUnamortizedCompensationExpense
12909000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P1Y8M15D
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19243000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7002000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29273000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42580000 usd
CY2024Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 usd
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 usd
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
38461000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36640000 usd
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5520000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3699000 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
61000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-895000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
199000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-696000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4261000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22369000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
26630000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
30000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
92000 usd
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
122000 usd
CY2023Q4 zyme Lease Liability
LeaseLiability
26752000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
881000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
2222000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
3702000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
3416000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
3284000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
3085000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
2990000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due After Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
7015000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
23492000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3461000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
20031000 usd
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
552000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
678000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
974000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1335000 usd
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
603000 usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
449000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
1021000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
835000 usd
CY2024Q2 zyme Operating Lease Termination
OperatingLeaseTermination
1033000 usd
CY2023Q2 zyme Operating Lease Termination
OperatingLeaseTermination
0 usd
zyme Operating Lease Termination
OperatingLeaseTermination
1033000 usd
zyme Operating Lease Termination
OperatingLeaseTermination
0 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
2188000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
1127000 usd
us-gaap Lease Cost
LeaseCost
3028000 usd
us-gaap Lease Cost
LeaseCost
2170000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32081000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19477000 usd
CY2024Q2 zyme Net Monetary Liabilities Denominated In Foreign Currency
NetMonetaryLiabilitiesDenominatedInForeignCurrency
727000 usd
CY2024Q2 zyme Net Monetary Liabilities Denominated In Foreign Currency
NetMonetaryLiabilitiesDenominatedInForeignCurrency
995000 cad
CY2024Q1 zyme Contingent Consideration Liability Fair Value Disclosure
ContingentConsiderationLiabilityFairValueDisclosure
1178000 usd
CY2024Q2 zyme Contingent Consideration Fair Value Adjustments
ContingentConsiderationFairValueAdjustments
-1178000 usd
CY2024Q2 zyme Contingent Consideration Liability Fair Value Disclosure Transfers
ContingentConsiderationLiabilityFairValueDisclosureTransfers
0 usd
CY2024Q2 zyme Contingent Consideration Liability Fair Value Disclosure
ContingentConsiderationLiabilityFairValueDisclosure
0 usd
CY2023Q4 zyme Contingent Consideration Liability Fair Value Disclosure
ContingentConsiderationLiabilityFairValueDisclosure
1878000 usd
zyme Contingent Consideration Fair Value Adjustments
ContingentConsiderationFairValueAdjustments
-1878000 usd
zyme Contingent Consideration Liability Fair Value Disclosure Transfers
ContingentConsiderationLiabilityFairValueDisclosureTransfers
0 usd
CY2024Q2 zyme Contingent Consideration Liability Fair Value Disclosure
ContingentConsiderationLiabilityFairValueDisclosure
0 usd
CY2023Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
1878000 usd
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001937653-24-000041-index-headers.html Edgar Link pending
0001937653-24-000041-index.html Edgar Link pending
0001937653-24-000041.txt Edgar Link pending
0001937653-24-000041-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zyme-20240630.htm Edgar Link pending
zyme-20240630.xsd Edgar Link pending
zyme-20240630xex102.htm Edgar Link pending
zyme-20240630xex311.htm Edgar Link pending
zyme-20240630xex312.htm Edgar Link pending
zyme-20240630xex321.htm Edgar Link pending
zyme-20240630xex322.htm Edgar Link pending
zyme-20240630_cal.xml Edgar Link unprocessable
zyme-20240630_def.xml Edgar Link unprocessable
zyme-20240630_lab.xml Edgar Link unprocessable
zyme-20240630_htm.xml Edgar Link completed
zyme-20240630_pre.xml Edgar Link unprocessable